From Sweta Jaiswal : President Trump’s latest move to raise the tariffs to 25% from 10% on $200 billion of Chinese goods might have ‘trumped’ hopes of many investors waiting for a truce between the two largest economies. However, amid this political conundrum, the biotech industry has kept its promise for solid returns so far. The rally […]
From Keris Lahiff: Biotech is blazing higher.
From ETF Trends: This article was originally published on ETFTrends.com.
From Sanghamitra Saha: This year, biotech stocks have seen their best-ever start to a year since 2012. A solid merger-and-acquisition momentum has been instrumental in this rally. The announcement of the mega-merger deal between Bristol-Myers (BMY – Free Report) and Celgene CELG at the beginning of 2019 has set the space on fire. Bristol-Myers has offered $74 billion to take over Celgene.
From Bertha Coombs: After brutal losses to end 2018, the biotech sector is off to the best start of the year since 2012.
From ETF Channel: Exchange traded funds (ETFs) trade just like stocks, but instead of ”shares” investors are actually buying and selling ”units”. These ”units” can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.
From Franklin Templeton Investments: Franklin Equity Group’s Evan McCulloch explains why higher rates of drug utilization and health care spending are lending support to the biotechnology and health care industries. He also gives his take on recent medical breakthroughs he thinks are likely to drive future growth.
From Zacks: The biotech sector has been performing remarkably well driven by a wave of mergers & acquisitions, new tax legislation, and a positive regulatory backdrop.
From Contrarian Outlook: Today I want to show you a beaten-down sector that has a long history of crushing the market–and 4 funds that should be on your radar now.
From Zacks: The biotech sector has been attracting a lot of investor attention lately. This sector is expected to continue benefiting from increased M&A activities, new drug approvals, better R&D and innovations.
From Dana Lyons: Left for dead after a bubbly blowoff in 2015, biotech stocks have finally clawed their way back to new highs.
From Zacks: So far, it’s been a good year for biotech stocks with the Nasdaq Biotechnology Index soaring 19.6% year to date.
Analyst/ETF Trader Paul Weisbruch of Street One Financial brings us his daily fund flows update, which today examines a relatively muted ETF landscape that’s seen smallish outflows in biotech and some renewed interest in volatility products ahead of earnings season.
From Zacks: The broader market was pretty eventful in the third quarter. While geopolitical and political concerns were rife, those threats couldn’t weigh on the equity market returns.
From Buzz Indexes: A common question we field relates to the transmission mechanism of sentiment to the share price: “How long does it take / when will it be reflected?”